NEW YORK ─ Renegade.bio on Tuesday announced it is partnering with Metabolomic Diagnostics to develop a preeclampsia risk screening test for the US market that the firms expect to launch late this year.
San Francisco-based Renegade.bio said the firms will jointly develop a test that measures a panel of biomarkers in blood as early indicators of preeclampsia risk and creates a personalized risk profile. The test aims to provide maternal health physicians with insights to better identify at-risk pregnancies and improve patient outcomes, the firm said.
Financial and other terms of the collaboration were not disclosed.
"Our partnership with Metabolomic Diagnostics demonstrates the mission of Renegade.bio to expand community-based health solutions beyond COVID-19 testing to include women’s reproductive and sexual health, particularly among traditionally underserved communities," Craig Rouskey, CEO and cofounder of Renegade.bio, said in a statement.
Cork, Ireland-based Metabolomic Diagnostics has a product pipeline that combines the biomarker multiplexing capabilities of mass spectrometry with its informatics and statistics solutions, Renegade.bio said.